Chester County News and Community Website
Immunome (NASDAQ: IMNM), headquartered in Exton, PA, is a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. Immunome’s proprietary discovery platform identifies novel therapeutic antibodies and their targets by leveraging highly educated components of the immune system, memory B cells, from patients whose bodies have learned to fight off their disease. For more information about the company, visit http://immunome.com.
EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced its third-quarter financial results ending September 30, 2023, and provided a corporate update that includes the completion of a significant merger …
Immunome Merges with Morphimmune, Secures $125M in Funding for Accelerated Cancer Therapy Development Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced the recent appointment of Jean-Jacques “JJ” Bienaimé to its Board of Directors. Mr. Bienaimé has over three decades of experience in the …
Immunome Appoints Jean-Jacques Bienaimé to Board of Directors Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) recently announced the appointment of Bob Lechleider, M.D., as Chief Medical Officer. Dr. Lechleider brings over 20 years of experience as an academic …
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced that it recently completed its previously announced merger with Morphimmune.
Immunome and Morphimmune Announce Successful Completion of Merger Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company, recently reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
Immunome Reports Second Quarter 2023 Financial Results Read More EXTON, PA — Immunome (Nasdaq: IMNM), a biopharmaceutical company, and Morphimmune, a private biotechnology company, announced that they recenlty entered into a definitive merger agreement.
Immunome and Morphimmune Announce Definitive Merger Agreement Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company, recently announced the publication of data highlighting efficacy of its preclinical IL-38 blocking antibody, titled “IL-38 blockade induces anti-tumor immunity …
Immunome Publishes Preclinical Research Demonstrating that Inhibition of IL-38 Using an Antibody Leads to Anti-Tumor Activity Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) reported financial results for the fourth quarter that ended December 31, 2022, and provided a corporate update.
Immunome Reports Fourth Quarter and Full Year 2022 Financial Results Read More EXTON, PA — Immunome, Inc. (Nasdaq: IMNM) announced the recent formation of an advisory board, comprised of Dr. John Lambert and Dr. Anthony Tolcher, to prioritize selection of novel targets …
Immunome Selects Key Opinion Leaders to Guide Drug Development Efforts Read More EXTON, PA — AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM) recently announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three …
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets Read More